Clinical trial NCT03742505: Rapid Normalization of Vitamin D Deficiency in PICU
Official title: Rapid Normalization of Vitamin D Deficiency in PICU: A Multi-Centre Phase III Double-Blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vitamin D Deficiency
Lead sponsor: Children's Hospital of Eastern Ontario
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
name: EURO-PHARM International Canada, Inc.
name: Canadian Critical Care Trials Group
First posted: 2018-11-15
Enrollment: 424
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Pragmatic, Phase III, multi-centre, double-blinded randomized controlled trial
Primary purpose: TREATMENT

Brief summary: Vitamin D plays an important role in calcium balance, heart and lung health, inflammation, infection prevention, and muscle strength. Due to these roles, it has been suggested that critically ill patients with low vitamin D levels might have higher rates of death and worse long-term health. We believe that identifying critically ill children with vitamin D deficiency and then restoring vitamin D levels quickly could represent a safe, easy and inexpensive means of reducing patient illness, preventing death and improving quality of life. This clinical trial will determine whether rapid normalization of vitamin D deficiency improves survival and health-related quality of life following critical illness. The VITdALIZE-KIDS trial is a multicentre randomized clinical trial in Canadian Pediatric Intensive Care Units (PICUs). Critically ill children who agree to participate (consent given by caregivers) will have their blood vitamin D level measured, and those who are vitamin D deficient will be randomized to receive a single dose of either high-dose vitamin D3 or placebo (no drug).

Study participants assigned to the high-dose vitamin D arm will receive 10,000 IU/kg of enteral cholecalciferol (up to a maximum of 400,000 IU). We have tested this dose in a pilot trial, and no patient experienced serious adverse events related to vitamin D administration. Patients will be followed for 90 days to determine whether they survived and had a significant change in their health and quality of life. Vitamin D deficiency is a common problem not only among critically ill Canadian children, but in PICUs worldwide. In addition to being applicable in Canada, our study protocol was designed to be generalizable and meaningful to critically ill children worldwide.

Detailed description: Rationale: Documented roles for vitamin D in calcium homeostasis, cardiovascular and respiratory health, innate immunity, and neuromuscular function have led to the hypothesis that vitamin D deficiency (VDD) represents a modifiable risk factor for outcomes in critical illness. Recently, dozens of adult and pediatric intensive care unit (ICU) studies have reported high deficiency rates (50% globally) and associations between VDD, organ dysfunction and mortality. Given the cumulative body of basic science and clinical literature, it has been hypothesized that high-dose vitamin D supplementation could improve ICU outcomes. Recent meta-analyses of multiple small to moderate sized adult clinical trials have suggested improvements in clinical outcome following high-dose supplementation, including survival. Two large multicentre trials have been initiated in the United States and Europe to confirm these findings. In contrast, the benefits and risks of rapid normalization of vitamin D status in the pediatric intensive care unit (PICU) have not been evaluated as part of a large multicentre clinical trial.

Study Design: VITdALIZE-KIDS is a Phase III double blind randomized clinical trial (RCT) to determine whether rapid normalization of VDD in critically ill children improves clinical outcome. In total, 766 critically ill children with VDD will be enrolled from PICUs in Canada.

Objectives: Primary: We will determine if rapid normalization of vitamin D status reduces the decline in health-related quality of life (HRQL), including mortality, that follows pediatric critical illness. Secondary: We will evaluate the impact of rapid normalization of vitamin D status on new or progressive multi-organ dysfunction.

Eligibility Criteria: 1) Admitted to PICU; 2) age 37 weeks corrected gestational age to \<18 years; 3) does not meet any exclusion criteria; and 4) blood 25 hydroxyvitamin D (25OHD) under 50 nmol/l. Patients meeting who meet all eligibility criteria and provide consent will be enrolled and randomized.

Interventions: Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU) or placebo equivalent in volume to the appropriate dose of cholecalciferol. This dose was evaluated in our pilot dose evaluation trial and shown to be effective (raised group 25OHD levels \>75 nmol/L in \>75% of participants) and safe (no cases of hypercalcemia or nephrocalcinosis, no difference in the rate of hypercalciuria between study arms). Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day).

Data Collection: Baseline HRQL (prior to admission) will be obtained within 72 hours of study enrollment. Follow-up measurements will be obtained in person (for patients who are still in hospital) or by telephone (for patients who have been discharged from hospital) at 28 and 90 days. Data on organ dysfunction, demographics, hospital course, adverse events, and health resource utilization will be collected throughout PICU and hospital stay. A blood sample collected at enrollment on Day 5 (range: Day 3-7) to determine 25OHD response and evaluate vitamin D axis functioning. A urine sample will be collected an enrollment and on Day 5 (range: Day 3-7) for analysis of calcium:creatinine ratio. Sample collection will only be done until 100 patients with full sample collection have been enrolled. Full sample collection is defined as one pre-intervention drug and urine sample and one post-intervention blood and urine sample.

Significance: High VDD rates in PICUs and the recognized interaction between vitamin D status and the health of multiple organ systems suggests vitamin D could represent an inexpensive and safe means of improving outcome. However, the true benefits or risks have not been evaluated in PICU in a clinical trial. The proposed trial seeks to address this question. Study findings will be used to inform guidelines for vitamin D supplementation in PICU, which will be easily generalizable to critically ill children worldwide.

Eligibility criteria: Inclusion Criteria:

* Admitted to PICU
* Corrected gestational age 37 weeks to age 18 years
* Vitamin D deficiency, as defined by blood 25OHD \< 50 nmol/L at the time of screening

Exclusion Criteria:

* Patient will be discharged from PICU before they can be enrolled (i.e. study drug administered) into the VITdALIZE-KIDS study and/or patient will be in hospital for \<3 days following enrollment
* Treating physician refuses enteral drug administration due to gastrointestinal disorder, and expects to do so for the full duration of the patient's PICU admission
* Persistent hypercalcemia (ionized calcium \>1.40 mmol/L (age \>2 months), \>1.45 (age \<2 months) excluding transient abnormalities and those related to parenteral calcium administration for hypocalcemia;
* Confirmed or suspected William's syndrome;
* Known nephrolithiasis or nephrocalcinosis;
* Imminent plan for withdrawal of treatment or transfer to another ICU not participating in the VITdALIZE-KIDS trial;
* Physician refusal;
* Previous enrollment in this trial;
* Granulomatous disease (tuberculosis or sarcoidosis);
* Severe liver failure;
* Hypersensitivity or allergy to vitamin D or any of the non-medicinal ingredients of the formulation;
* Patient on thiazide diuretics also receiving regular ongoing calcium supplementation above the daily recommended intake;
* Adolescent female of child-bearing age with a positive pregnancy serum test;
* Patient on digoxin-therapy; and
* Treating physician intends to administer vitamin D doses above 1000 IU (e.g. patient presents with isolated clinical symptoms of severe VDD, severe burns).

Primary outcomes:
measure: Health related quality of life
timeFrame: 28 days
Secondary outcomes:
measure: New and/or progressive multiple organ dysfunction
timeFrame: 28 days
Other outcomes:
measure: Functional status
timeFrame: 28 and 90 days
measure: Mortality
timeFrame: 28 and 90 days
measure: PICU length of stay
timeFrame: Up to 90 days post-randomization
measure: Hospital length of stay
timeFrame: Up to 90 days post-randomization
measure: Serious adverse events
timeFrame: Randomization to 90 days post-randomization
measure: Vitamin D toxicity
timeFrame: Randomization to 90 days post-randomization
measure: Change in vitamin D status and axis functioning
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
measure: Metabolomic profiling
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
measure: Biomarker Analysis - C-Reactive Protein
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
measure: Biomarker Analysis - Pro-inflammatory cytokines
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
measure: Biomarker Analysis - Anti-inflammatory cytokines
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
measure: Biomarker Analysis - Brain natriuretic peptide
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
measure: Biomarker Analysis - Cathelicidin
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
measure: Biomarker Analysis - Bone markers
timeFrame: Enrolment and on >48 hours following enrollment (range: Day 2-7)
Locations:
city: Calgary
country: Canada
facility: Alberta Children's Hospital
state: Alberta
city: Edmonton
country: Canada
facility: Stollery Children's Hospital
state: Alberta
city: Vancouver
country: Canada
facility: BC Children's Hospital
state: British Columbia
city: Halifax
country: Canada
facility: IWK Health Centre
state: Nova Scotia
city: Hamilton
country: Canada
facility: McMaster Children's Hospital
state: Ontario
city: London
country: Canada
facility: Division of Critical Care, Department of Pediatrics, Victoria Hospital
state: Ontario
city: Ottawa
country: Canada
facility: Children's Hospital of Eastern Ontario
state: Ontario
city: Toronto
country: Canada
facility: The Hospital for Sick Children
state: Ontario
city: Montreal
country: Canada
facility: Montreal Children's Hospital
state: Quebec
city: Montréal
country: Canada
facility: Centre hospitalier universitaire Sainte-Justine
state: Quebec
Study officials:
affiliation: Children's Hospital of Eastern Ontario
name: Dayre McNally, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: